Eli Lilly’s Verzenio (abemaciclib) received FDA approval for a third indication — the combined use with an aromatase inhibitor as an initial endocrine-based therapy to treat postmenopausal women with HR+, HER2- advanced or metastatic breast cancer.

The drug received its initial approval in September, making it the first cyclin-dependent kinase 4 & 6 inhibitor approved for solo and combined use in treating metastatic breast cancer.

The expanded approval was supported by the efficacy and safety results of the MONARCH 3 clinical trial.